Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from InnoCare Pharma Ltd. ( (HK:9969) ) is now available.
InnoCare Pharma Ltd. has released its unaudited financial data for the third quarter of 2025, prepared according to Chinese accounting principles and intended for the STAR Market of the Shanghai Stock Exchange. Additionally, the company announced a change in the composition of its Nomination Committee, with Prof. Kunliang Guan joining and Ms. Lan Hu stepping down, to enhance corporate governance and diversity in response to recent amendments to the Corporate Governance Code.
The most recent analyst rating on (HK:9969) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a pharmaceutical company incorporated in the Cayman Islands, focusing on innovative drug development and commercialization. The company operates in the healthcare industry and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 16,424,363
Technical Sentiment Signal: Buy
Current Market Cap: HK$21.79B
Find detailed analytics on 9969 stock on TipRanks’ Stock Analysis page.